The standard advice about injection-site reactions assumes that technique is the whole story: rotate properly, and you will be fine. Technique matters, but the labels tell a more interesting story. The rates differ several-fold across this class of medicines, and on both tirzepatide products the labels carry the same striking finding: reactions were far more frequent in the patients whose immune systems made antibodies to the drug. That is a property of the person, not of the injection, and it changes what a recurring lump at one spot actually means.
This page covers the reaction itself: what the labels report, how often, what they name, and where the limits of the usual advice are. The prevention habit, rotating sites deliberately, already has its own page at GLP-1 Injection Site Rotation: Why It Matters and How to Track It, and blood under the skin, a different subject, is at Bruising at Injection Sites: Normal, Preventable, or Neither?.
What the labels report, product by product
Open the adverse reactions sections and the class splits cleanly in two. In clinical trials in adults for weight reduction, 1.4 percent of Wegovy treated patients and 1 percent of patients receiving placebo experienced injection site reactions, a list the label fills in as pruritus, erythema, inflammation, induration and irritation. In placebo-controlled trials, injection site reactions such as discomfort and erythema were reported in 0.2 percent of Ozempic treated patients. On the semaglutide products, in other words, these reactions are uncommon and barely above placebo.
The tirzepatide products report several times more. In the pool of placebo-controlled trials in adults, injection site reactions were reported in 3.2 percent of Mounjaro treated patients compared to 0.4 percent of placebo treated patients. On Zepbound, injection site reactions appear among the most common adverse reactions reported in at least 5 percent of treated patients, and the adverse reaction table shows 2 percent on placebo against 6, 8 and 8 percent across the dose groups, with the label rolling together the terms injection site bruising, erythema, pruritus, pain, rash and reaction.
| Product | Treated patients | Placebo |
|---|---|---|
| Ozempic (semaglutide) | 0.2% | Not reported |
| Wegovy (semaglutide) | 1.4% | 1% |
| Mounjaro (tirzepatide) | 3.2% | 0.4% |
| Zepbound (tirzepatide) | 6 to 8% across dose groups | 2% |
That spread is what the labels report, and it is not an argument for one product over another. Nobody chooses a medicine on injection-site reaction rates, the choice belongs to the prescriber, and a higher tabulated rate still describes a minority of patients. What the spread does mean is that two people on two different products can have honestly different experiences of the same skin.
It also means the fair comparison for any product is its own placebo column, not another product's table. Wegovy's 1.4 percent sits against 1 percent on placebo, so almost the entire figure is background noise that would have happened anyway; Mounjaro's 3.2 percent sits against 0.4 percent, a very different relationship. Percentages without their placebo companions mislead in both directions, on this subject and on every other one in the adverse reactions section.
A note on expectation, since the word lump sits in this article's title and deserves steadier handling than dread. The labels count events and name terms; they do not characterize how the typical event behaves afterward, and neither will we. Some reactions are brief and quiet, some recur, and what any particular one is doing on your skin is a question for the clinician who can examine it. The number worth holding from the tables is the smaller one: on every product in the class, most treated patients never report an injection site reaction at all.
The antibody finding
Now the part that makes this subject worth a page of its own. In Zepbound treated patients in a pool of two studies, injection site reactions were more frequent in those with anti-tirzepatide antibodies, 11.3 percent, compared to those who did not develop anti-tirzepatide antibodies, 1 percent. The Mounjaro label reports the same pattern across a pool of seven clinical trials: reactions occurred in 119 of 2,570 treated adult patients with anti-tirzepatide antibodies, 4.6 percent, and in 18 of 2,455 of those who did not develop them, 0.7 percent. In the pediatric trial the counts were small in the same direction: 3 of 50 treated patients with antibodies against 0 of 43 without.
Roughly a tenfold difference on the Zepbound data, and several-fold on Mounjaro's, tracking not with how well people inject but with whether their immune system produced antibodies against the drug. This is individual biology. It explains why the most careful injector can be the one reacting and the sloppiest can be the one who never does, and it is worth knowing before concluding that a recurring reaction must mean you are doing something wrong.
GLP 1 Tracker AppInjection site notes on every dose entry, beside a side effect diary with severity. A record of which spot reacted, when, is what a clinician can actually read.
Get the app
What the labels name, and what they do not
When the labels describe these reactions, they use their own vocabulary: pruritus, erythema, inflammation, induration, irritation, bruising, pain and rash. In ordinary words, itching, redness, swelling, firmness of the skin, soreness and visible marks. That is where the labels stop. They do not narrate how an individual lump behaves, how long it lasts or what any particular one means, and this article will not invent descriptions they decline to give. What a specific lump under your skin turns out to be is a question for a clinician who can look at it, full stop.
Technique still matters, it is just not the whole story
None of the above cancels the basics, because the basics are real regardless of antibodies. Rotate sites rather than returning to the same convenient spot, use a fresh needle every injection rather than reusing one, and do not inject into skin that is bruised, scarred or tender. Why a fresh needle matters each time is its own small subject, at Do GLP-1 Pens Need Separate Needles?
One term deserves careful attribution. Lipohypertrophy, fatty changes under the skin from repeated injection into the same area, is a recognized phenomenon in injection practice generally, particularly with insulin, and it is a reason rotation is taught. None of the GLP-1 labels we are quoting mentions it, and this article does not put the word in their mouths. The rotation habit, and how to keep it honest with a log, is the heart of the rotation page linked above.
When it belongs with a clinician
The labels carry separate warnings for hypersensitivity, and this article routes there rather than describing them: a reaction that spreads, worsens, or comes with any symptom affecting the whole body belongs with a clinician promptly, not with a diary. For everything quieter, the diary is precisely the tool. A site note on each dose entry, with what the skin did and when, is what turns the feeling that one spot always reacts into something a prescriber can read at an appointment, alongside the rest of the record. The habits of that diary are covered at How to Track GLP-1 Side Effects (and What to Show Your Doctor).
That is the whole picture the labels allow: honest rates that differ across the class, names for what was seen, an antibody finding that moves the explanation from technique toward biology, and a clear line where a clinician takes over. Inject carefully, note what happens, and let the record do the talking.
Frequently asked questions
Are injection-site reactions common on GLP-1s?
It depends heavily on the product, per the prescribing information. In clinical trials for weight reduction, 1.4 percent of Wegovy treated patients had injection site reactions against 1 percent on placebo, and in placebo-controlled trials 0.2 percent of Ozempic treated patients reported them. The tirzepatide products run higher: 3.2 percent on Mounjaro against 0.4 percent on placebo, and on Zepbound the rates reached 8 percent across dose groups against 2 percent on placebo.
Why do I get a lump or itching at my injection site but my friend does not?
The most interesting answer in the labels has nothing to do with technique. On both tirzepatide products, injection site reactions were far more frequent in patients who developed antibodies to the drug. On Zepbound the figures were 11.3 percent with anti-tirzepatide antibodies against 1 percent without, and on Mounjaro 4.6 percent against 0.7 percent. Whether your immune system makes those antibodies is individual biology, which is why two people injecting the same way can have very different skin.
What do injection-site reactions look like on these medicines?
The labels name what trials saw, in their own terms: pruritus, which is itching, erythema, which is redness, inflammation, induration, which is firmness or thickening, irritation, bruising, pain and rash. What any individual lump turns out to be is a question for a clinician, not an article, and the labels describe trial counts rather than how any single reaction behaves or resolves. A note with the date, site and description is what makes a pattern visible.
When does an injection-site reaction need a doctor?
The labels route spreading, worsening or whole-body symptoms to the hypersensitivity warnings rather than to home management, and this article does the same in one sentence: a reaction that spreads beyond the site, worsens over time, or arrives with any symptom affecting the whole body belongs with a clinician promptly. An ordinary localized reaction that settles is a different matter, and a dated log of site notes is the thing that helps a prescriber tell the two apart at an appointment.
Can I log my injection site in the app?
Yes. GLP 1 Tracker includes injection site notes with every dose entry, alongside a side effect diary with severity. That is what turns a feeling that one spot always reacts into a readable record: site, date, what the skin did. The app never suggests doses or site choices; it holds the observations you and your prescriber make decisions with, and everything stays on your phone.